Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT06355388 Not yet recruiting - Heart Failure Clinical Trials

TRAnscutaneous vaGUS Nerve Stimulation in Patients With Chronic Heart Failure

TRAGUS-HF
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

To verify the efficacy of transcutaneous vagus nerve stimulation (tVNS) on and autonomic balance in patients with chronic heart failure and reduced (HFrEF) or mildly reduced (HFmrEF) left ventricular ejection fraction. The study hypothesis is that tVNS increases baroreflex gain, with consequent benefits on sympathovagal balance (at short- and mid-term), and on quality of life and bio-humoral parameters (at mid-term).

NCT ID: NCT06355310 Not yet recruiting - Clinical trials for Non-Alcoholic Fatty Liver Disease

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

SHIELD
Start date: May 20, 2024
Phase: Phase 2
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

NCT ID: NCT06355102 Not yet recruiting - Tinnitus Clinical Trials

The Development of Tinnitus in Patients With SSNHL: Insights From fMRI and Metabolomics

Start date: April 15, 2024
Phase:
Study type: Observational

The goal of this clinical trial is to investigate the factors and mechanisms underlying tinnitus generation and chronification in patients with sudden sensorineural hearing loss (SSNHL) . The main questions it aims to answer are: - What are the peripheral and central influencing factors that contribute to tinnitus in patients with SSNHL? - Can serum metabolic biomarkers be identified to predict and monitor tinnitus prognosis in these patients? Participants in this study will include patients with SSNHL and tinnitus, patients with SSNHL without tinnitus, and healthy subjects. They will be asked to undergo a series of assessments, including audiological tests, vestibular function examinations, and functional magnetic resonance imaging (fMRI). Additionally, blood samples will be collected for metabolomics analysis. Investigators will compare the brain functional states and serum metabolite profiles of patients with SSNHL and tinnitus to those without tinnitus. Morever, tinnitus symptom characteristics, audiological outcomes, and brain functional states will be assessed during time.

NCT ID: NCT06354790 Not yet recruiting - Clinical trials for Merosin Deficient Congenital Muscular Dystrophy

Natural History Study of Children With LAMA2-related Dystrophies

LAMA2
Start date: June 15, 2024
Phase:
Study type: Observational

The goal of this natural history study is to characterize the disease course, characteristics in paediatric population of LAMA2-RD (related dystrophies) patients. The aim of the study is to establish a well-described cohort of patients in France with LAMA2-RD for prospective follow-up and recruitment for future clinical trials. Participants will be follow up during a two years period regarding exhaustive aspects of the pathology: - Muscular function - Respiratory function - Cognitive phenotyping - Quality of life - Growth parameters - Biomarkers

NCT ID: NCT06354010 Not yet recruiting - Clinical trials for Sensorineural Hearing Loss, Bilateral

Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis

SONG
Start date: May 2024
Phase:
Study type: Observational

The purpose of this study is to characterize and assess the evolution of hearing impairment of patients with adulthood-onset bilateral sensorineural hearing loss carrying mutations on GJB2 gene.

NCT ID: NCT06353750 Not yet recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Intracellular Magnesium and Heart Failure

Start date: April 15, 2024
Phase:
Study type: Observational

Low magnesium levels are surprisingly common in those with a heart condition known as HFpEF, where the heart pumps well but is too rigid to fill properly with blood. While routine blood tests can check magnesium levels, they don't tell us how much magnesium is actually inside the heart and muscle cells, where it's vital for energy and overall function. Our research aims to get a clearer picture by looking directly at the magnesium inside these cells and understanding its role in the body's energy production and usage. We're also interested in how magnesium levels affect symptoms and the body's handling of sugar. We're using advanced medical imaging techniques, like heart magnetic resonance imaging (MRI) and other heart and muscle function tests, at rest and when the heart is working hard to help answer these questions. We'll compare the magnesium levels inside the cells before and after giving a supplement of magnesium to see if this can make a difference in how the heart and muscles work.

NCT ID: NCT06353412 Not yet recruiting - Clinical trials for IIH - Idiopathic Intracranial Hypertension

Current Treatment Methods of Idiopathic Intracranial Hypertension

Start date: June 1, 2024
Phase:
Study type: Observational

Aim of the study : 1. to determine the response to each treatment plan. 2. to determine when to choose specific treatment method. 3. to determine complication of each type of treatment method

NCT ID: NCT06353373 Not yet recruiting - Clinical trials for Venous Thromboembolism

Smart Technology Facilitated Venous Thromboembolism Prophylaxis Based on Bundled Evidence-based Prevention Strategies

SmaVTE-BEST
Start date: September 1, 2024
Phase:
Study type: Observational

Venous thromboembolism (VTE) is the third leading cause of cardiovascular disease deaths globally, and its incidence is increasing over the years. Hospital-acquired VTE accounts for approximately 75% of all deaths attributed to VTE. However, only half of patients with indications for VTE prophylaxis take preventive measures, and high rates of inappropriate VTE prophylaxis prescribing contribute to the gap between VTE prophylaxis and guidelines. To further minimize the gap between clinical practice and guidelines, a range of strategies have been employed across various fields of VTE prophylaxis. One of the most effective measures is the utilization of a Clinical Decision Support System (CDSS). Smart technology-based CDSS facilitates automated evaluation of VTE risk and detection, addressing issues at both the beginning and end of the in-hospital VTE prevention process. but there is still a lack of research on how to effectively implement evidence-based VTE prophylaxis in the middle of the process. In our hospital, routine use of DeVTEcare system (a CDSS for VTE risk assessment and integrated care) for in-hospital management of VTE has been launched since 2021. This study aims to investigate the effect of integrating bundled guideline-based VTE prevention strategies into the DeVTEcare system on in-hospital VTE prophylaxis.

NCT ID: NCT06353282 Not yet recruiting - Adolescents Clinical Trials

MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents

Start date: July 1, 2025
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the safety and feasibility of 3,4-methylenedioxymethamphetamine (MDMA) -assisted psychotherapy to treat resistant post-traumatic stress disorder (PTSD). The secondary objectives are the exploration of effectiveness for treatment-resistant PTSD, symptoms of depression, and anxiety symptoms.

NCT ID: NCT06352944 Not yet recruiting - Clinical trials for Non-cystic Fibrosis Bronchiectasis

Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children

Start date: July 2024
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to evaluate the role of procalcitonin in bronchoalveolar lavage as a biomarker for assessment of severity of non-CF bronchiectasis in children in correlation with other markers (functional and radiological severity )